Business Wire - November 10, 2008
SASSARI, Italy & PRINCETON, N.J.--ViroStatics, srl today announced Chief Development Officer Dr. Michael Stevens will present a Company overview during Rodman & Renshaw's Tenth Annual Global Healthcare Conference taking place November 10 through 12, 2008 at the New York Palace Hotel. Rodman & Renshaw is a leading investment banking firm with particular emphasis on "essential" industries, including health care. The conference, which also features a keynote address by former U.S. President, Bill Clinton, hosts more than 550 companies from across the globe presenting to over 1000 registered institutional investors.
ViroStatics' presentation takes place on Wednesday, November 12th at 4:05 PM (EST) in the Louis Room during which Dr. Stevens will review and update the Company's recent developments in drug discovery and development as well as the development of proprietary biomarker assays. In the presentation, Dr. Stevens will review how virostatic drugs represent a new family of antivirals designed not only to suppress viruses but also to preserve the immune system from chronic damage. In particular, he will present the Company's lead developmental product, VS411 - a fixed combination of virostatic drugs undergoing Phase II clinical development for the treatment of HIV believed to be the first in this new class of drugs.
About ViroStatics
ViroStatics srl, an Italian pharmaceutical company with operations in Sassari and Pavia, Italy and Princeton, NJ, is committed to discovering and developing novel combination therapeutics to address significant medical needs in HIV/AIDS, chronic infections and related fields. The company is developing its lead product, VS411, as the first fixed-dose combination of two drugs that not only decrease HIV replication but also protect and conserve the immune system. VS411 has completed Phase I and is now undergoing evaluation in a multinational Phase II development program. ViroStatics has also developed novel biomarker assays and a proprietary screening methodology to rapidly and efficiently identify cytostatic agents with potential to inhibit viral replication and control the over-stimulation of the immune system that is believed to drive the progression of HIV to AIDS. ViroStatics is committed to expanding its pipeline and product portfolio by in-licensing early- and late-stage compounds and exploring co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals.
Contacts
ViroStatics srl | Michael Stevens, PharmD, 609-987-2305 | Chief Development Officer | m.stevens@virostatics.com | www.virostatics.com
081110
BW081114
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .